HIGHLIGHTS
- who: American Medical Association from the Department University Cancer Institute have published the research: Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups, in the Journal: (JOURNAL) of June/30,/2022
- how: Most RCTs that have investigated the effectiveness of first-line anti-PD-1-based regimens in advanced ESCC focused mainly on the overall randomly assigned sample and PD-L1-positive (CPS u226510 or TPS u22651%) subgroup without reporting the Kaplan-Meier (KM) curves for patients with KMSubtraction in the landscape of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.